📰 Vor Bio News
Vor Bio News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Vor Bio. Real-time updates on events, politics, business and more.
June 4, 2024
04.06.2024 - CAMBRIDGE, Mass., June 04, 2024 (GLOBE NEWSWIRE) - Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of June 1, 2024, the Compensation Committee of the Board of Directors granted stock ...
April 25, 2024
Significant operational and clinical progress in 2023 and early 2024 with maturation of Internal Programs,1 launch of two new Founded Entities,2 including a $100 million Series A financing for...
December 22, 2023
21.12.2023 - CAMBRIDGE, Mass., Dec. 21, 2023 (GLOBE NEWSWIRE) - Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of December 20, 2023, the Compensation Committee of the Board of Directors granted ...
December 21, 2023
CAMBRIDGE, Mass., Dec. 21, 2023 -- Vor Bio , a clinical-stage cell and genome engineering company, today announced that, effective as of December 20, 2023, the Compensation Committee of the Board...
November 9, 2023
Primary neutrophil engraftment of trem-cel achieved in all seven patients treated to date • All three patients receiving multiple Mylotarg™ doses exhibited…
November 6, 2023
Operator: Good morning, and welcome to Editas Medicines Third Quarter Conference Call. All participants are now in listen-only mode.
November 5, 2023
Editas Medicine, Inc. (NASDAQ:EDIT) Q3 2023 Earnings Call Transcript November 3, 2023 Editas Medicine, Inc. beats earnings expectations. Reported EPS is $-0.00055, expectations were $-0.64. Operator: Good morning, and welcome to Editas Medicine’s Third Quarter Conference Call. All participants are now in listen-only mode. There will be a question-and-answer session at the end of this […]
November 3, 2023
Company to provide a clinical update on the EDIT-301 RUBY trial for SCD and EdiTHAL trial for TDT in December at the American Society of Hematology Annual Meeting and in a Company-sponsored webinar ...
August 10, 2023
Cure blood cancers through cell and genome engineering August 2023 Disclaimer This presentation contains... -Today at 04:31 pm- MarketScreener
August 10, 2023
Next trem-cel clinical data update expected by year-end 2023VCAR33ALLO IND cleared by U.S. FDA; Rapidly activating sites toward study initiationSecured non-exclusive license to Cas9 gene-edited HSCs... -Today at 04:07 pm- MarketScreener